The DOI matches its Crossref record.
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
Open accessAbstract
BACKGROUND: Predict (www.predict.nhs.uk) is an online, breast cancer prognostication and treatment benefit tool. The aim of this study was to incorporate the prognostic effect of HER2 status in a new version (Predict+), and to compare its performance with the original Predict and Adjuvant!. METHODS: The prognostic effect of HER2 status was based on an analysis of data from 10 179 breast cancer patients from 14 studies in the Breast Cancer Association Consortium. The hazard ratio estimates were incorporated into Predict. The validation study was based on 1653 patients with early-stage invasive breast cancer identified from the British Columbia Breast Cancer Outcomes Unit. Predicted overall survival (OS) and breast cancer-specific survival (BCSS) for Predict+, Predict and Adjuvant! were compared with observed outcomes. RESULTS: All three models performed well for both OS and BCSS. Both Predict models provided better BCSS estimates than Adjuvant!. In the subset of patients with HER2-positive tumours, Predict+ performed substantially better than the other two models for both OS and BCSS. CONCLUSION: Predict+ is the first clinical breast cancer prognostication tool that includes tumour HER2 status. Use of the model might lead to more accurate absolute treatment benefit predictions for individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Self-citationBinuya, M. A. E., Engelhardt, E. G., Schats, W., Schmidt, M. K., & Steyerberg, E. W. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01801-8 · Cited by 246
Self-citationClift, A. K., Dodwell, D., Lord, S., Petrou, S., Brady, M., Collins, G. S., & Hippisley-Cox, J. (2023) · BMJ · doi:10.1136/bmj-2022-073800 · Cited by 97
Shamai, G., Cohen, S., Binenbaum, Y., Sabo, E., Cretu, A., Mayer, C., Barshack, I., Goldman, T., Bar-Sela, G., Polónia, A., et al. (2025) · doi:10.1101/2025.05.15.25327686 · Cited by 3
Metadata
- Authors
- Wishart, G. C., Bajdik, C. D., Dicks, E., Provenzano, E., Schmidt, M. K., Sherman, M., Greenberg, D. C., Green, A. R., Gelmon, K. A., Kosma, V.-M., Olson, J. E., Beckmann, M. W., Winqvist, R., Cross, S. S., Severi, G., Huntsman, D., Pylkäs, K., Ellis, I., Nielsen, T. O., Giles, G., Blomqvist, C., Fasching, P. A., Couch, F. J., Rakha, E., Foulkes, W. D., Blows, F. M., Bégin, L. R., van't Veer, L. J., Southey, M., Nevanlinna, H., Mannermaa, A., Cox, A., Cheang, M., Baglietto, L., Caldas, C., Garcia-Closas, M., & Pharoah, P. D. P.
- Venue
- British Journal of Cancer
- Published
- 2012-07-31
- Volume
- 107
- Issue
- 5
- Pages
- 800-807
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2169344399
- Cited by
- 196
- References
- 0
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. https://app.cochat.ai/papers/10.1038/bjc.2012.338
- The paper
- Wishart, G. C., Bajdik, C. D., Dicks, E., Provenzano, E., Schmidt, M. K., Sherman, M., Greenberg, D. C., Green, A. R., Gelmon, K. A., Kosma, V.-M., Olson, J. E., Beckmann, M. W., Winqvist, R., Cross, S. S., Severi, G., Huntsman, D., Pylkäs, K., Ellis, I., Nielsen, T. O., . . . Pharoah, P. D. P. (2012). PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. British Journal of Cancer. https://doi.org/10.1038/bjc.2012.338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.